Abstract
This study uses Medicaid drug utilization data to describe reimbursement and market share of long-acting insulins before and after approval of new insulin products and to estimate savings associated with a “biosimilar” for insulin glargine approved in 2015.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Biosimilar Pharmaceuticals / economics*
-
Biosimilar Pharmaceuticals / therapeutic use
-
Cost Savings
-
Drug Costs / trends
-
Drug Utilization / economics
-
Drug Utilization / trends*
-
Humans
-
Insulin Glargine / therapeutic use
-
Insulin, Long-Acting / economics*
-
Insulin, Long-Acting / therapeutic use
-
Insurance, Health, Reimbursement / trends*
-
Medicaid / economics
-
Medicaid / trends*
-
United States
Substances
-
Biosimilar Pharmaceuticals
-
Insulin, Long-Acting
-
Insulin Glargine